[go: up one dir, main page]

DK1796668T3 - Vandigt farmaceutisk præparat der omfatter roflumilast - Google Patents

Vandigt farmaceutisk præparat der omfatter roflumilast

Info

Publication number
DK1796668T3
DK1796668T3 DK05794694T DK05794694T DK1796668T3 DK 1796668 T3 DK1796668 T3 DK 1796668T3 DK 05794694 T DK05794694 T DK 05794694T DK 05794694 T DK05794694 T DK 05794694T DK 1796668 T3 DK1796668 T3 DK 1796668T3
Authority
DK
Denmark
Prior art keywords
roflumilast
aqueous pharmaceutical
pharmaceutical composition
administration
aqueous
Prior art date
Application number
DK05794694T
Other languages
Danish (da)
English (en)
Inventor
Rudolf Linder
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Application granted granted Critical
Publication of DK1796668T3 publication Critical patent/DK1796668T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Farming Of Fish And Shellfish (AREA)
DK05794694T 2004-09-22 2005-09-21 Vandigt farmaceutisk præparat der omfatter roflumilast DK1796668T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004046235A DE102004046235A1 (de) 2004-09-22 2004-09-22 Arzneimittelzubereitung
PCT/EP2005/054723 WO2006032675A1 (en) 2004-09-22 2005-09-21 Aqueous pharmaceutical preparation comprising roflumilast

Publications (1)

Publication Number Publication Date
DK1796668T3 true DK1796668T3 (da) 2009-02-02

Family

ID=35447576

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05794694T DK1796668T3 (da) 2004-09-22 2005-09-21 Vandigt farmaceutisk præparat der omfatter roflumilast

Country Status (17)

Country Link
US (1) US9205044B2 (sl)
EP (1) EP1796668B1 (sl)
JP (1) JP5044404B2 (sl)
AT (1) ATE408405T1 (sl)
AU (1) AU2005286476B2 (sl)
CA (1) CA2580397C (sl)
CY (1) CY1109407T1 (sl)
DE (2) DE102004046235A1 (sl)
DK (1) DK1796668T3 (sl)
ES (1) ES2314718T3 (sl)
HR (1) HRP20080640T3 (sl)
ME (1) ME01050B (sl)
PL (1) PL1796668T3 (sl)
PT (1) PT1796668E (sl)
RS (1) RS50641B (sl)
SI (1) SI1796668T1 (sl)
WO (1) WO2006032675A1 (sl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
KR20110056516A (ko) * 2008-09-12 2011-05-30 크리티컬 파머수티컬스 리미티드 점막 또는 피부를 통한 치료제의 흡수 개선
US10519504B2 (en) 2009-05-11 2019-12-31 Berg Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
US11400058B2 (en) 2010-03-12 2022-08-02 Berg Llc Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof
ES2711100T3 (es) * 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
EP2694463B8 (en) 2011-04-04 2019-10-09 Berg LLC Treating central nervous system tumors with coenzyme q10
CN102793684B (zh) * 2011-05-26 2016-02-17 杭州赛利药物研究所有限公司 罗氟司特液体制剂及其制备方法
EA201490047A1 (ru) 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
EA032775B1 (ru) 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
WO2015022418A1 (en) 2013-08-16 2015-02-19 Takeda Gmbh Treatment of cognitive impairment with pde4 inhibitor
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
CN105287366B (zh) * 2014-06-18 2018-02-16 张蕊 一种维生素k1注射液及其制备方法
US9969688B2 (en) 2014-10-24 2018-05-15 Hisamitsu Pharmaceutical Co., Inc. Roflumilast prodrugs
EP3319608A4 (en) * 2015-07-07 2019-04-03 LifeRaft Biosciences, Inc. POLOXAMER 188 FORMULATIONS WITH REDUCED SODIUM AND METHOD OF USE
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN112384199A (zh) 2018-06-04 2021-02-19 阿尔库缇斯股份有限公司 改善罗氟司特皮肤渗透滞后时间的方法和制剂
KR102117525B1 (ko) * 2018-07-09 2020-06-01 건양대학교 산학협력단 Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
JP2023513092A (ja) 2020-01-31 2023-03-30 アーキュティス・バイオセラピューティクス・インコーポレーテッド 向上した送達および血漿半減期を有する局所用ロフルミラスト配合物
EP4101469A4 (en) * 2020-02-03 2024-05-29 Senju Pharmaceutical Co., Ltd. USE OF A POLYETHER COMPOUND
AU2021393513A1 (en) 2020-12-04 2023-07-06 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
WO2022169615A1 (en) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
JP2024506384A (ja) 2021-02-10 2024-02-13 イオリクス セラピューティクス，インコーポレーテッド ロフルミラストの眼科的送達方法
US12263160B2 (en) 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
US12453721B2 (en) 2021-12-28 2025-10-28 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
JP2025530005A (ja) 2022-09-15 2025-09-09 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100331255B1 (ko) 1993-07-02 2002-10-25 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도
JP2002513773A (ja) * 1998-05-07 2002-05-14 コリクサ コーポレイション アジュバント組成物及びその使用法
PT1161239E (pt) 1999-03-10 2005-02-28 Altana Pharma Ag 3-ciclopropilmetoxi-4-difluorometoxi-n-(3,5-dicloropirid-4-il)-benzamida para o tratamento da esclerose multipla
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
HUE039709T2 (hu) * 2002-05-28 2019-01-28 Astrazeneca Ab Helyileg alkalmazandó gyógyászati készítmény
US20030235631A1 (en) * 2002-06-17 2003-12-25 Pfizer Inc. Combination treatment for depression and anxiety
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
CN101745112A (zh) * 2002-07-19 2010-06-23 艾博特生物技术有限公司 TNFα相关疾病的治疗

Also Published As

Publication number Publication date
ES2314718T3 (es) 2009-03-16
CA2580397A1 (en) 2006-03-30
ATE408405T1 (de) 2008-10-15
AU2005286476B2 (en) 2011-11-10
DE102004046235A1 (de) 2006-03-30
HRP20080640T3 (en) 2009-01-31
CA2580397C (en) 2013-07-30
SI1796668T1 (sl) 2009-02-28
DE602005009848D1 (de) 2008-10-30
EP1796668B1 (en) 2008-09-17
PT1796668E (pt) 2008-12-22
ME01050B (me) 2012-10-20
RS50641B (sr) 2010-06-30
EP1796668A1 (en) 2007-06-20
WO2006032675A1 (en) 2006-03-30
PL1796668T3 (pl) 2009-02-27
US20070259009A1 (en) 2007-11-08
JP2008513416A (ja) 2008-05-01
JP5044404B2 (ja) 2012-10-10
CY1109407T1 (el) 2014-07-02
US9205044B2 (en) 2015-12-08
AU2005286476A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
DK1796668T3 (da) Vandigt farmaceutisk præparat der omfatter roflumilast
MEP43508A (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
NO20090175L (no) Stabile laquinimod sammensetninger
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
NO20072258L (no) Farmasøytiske sammensetninger omfattende et camptothecinderivat
BRPI0513184A (pt) derivados de 2-carbamida-4-feniltiazol, preparação dos mesmos e aplicação dos mesmos em terapia
GEP20105083B (en) A solid pharmaceutical dosage formulation
BRPI0512938A (pt) derivados da quinazolinediona como inibidores parp
NO20070785L (no) Sammensetninger for levering av svaert vannloselige medikamenter.
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
ATE534645T1 (de) Kaliumsalz eines hiv-integrasehemmers
EA200900135A1 (ru) Производные пиразола в качестве ингибиторов цитохрома р450
DK1776010T3 (da) Fremgangsmåde til fremstilling af vandige aktivstofsammensætninger af aktivstoffer, som er tungt oplöselige i vand
BRPI0507654A (pt) composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteìna de fusão de rsv
DK1678162T3 (da) P-glycoprotein-inhibitor, fremgangsmåde til fremstilling heraf og farmaceutisk sammensætning omfattende denne
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CR9058A (es) Derivados de indol como inhibidores de la adenilato ciclasa soluble
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
GEP20115222B (en) New pharmaceutical compounds
ATE401863T1 (de) Neue viskoelastische zusammensetzung umfassend alginat und vitamin e tpgs oder tpgsa
ATE511837T1 (de) Wässrige arzneimittelformulierung von 4-ä((4- carboxybutyl)-ä2-ä(4-phenethyl-benzyl)oxyü- phenethylüamino)methylübenzoesäure
BRPI0514724A (pt) inibidores da enzima hiv integrase
TW200624429A (en) Novel cysteine protease inhibitors
ECSP045213A (es) Aminas de fenilpirimidina como inhibidores ige
AR029091A1 (es) Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparacion de un medicamento con efecto antagonista de n-metil-d-aspartato-(nmda)